Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Consensus Based Diagnostic and Therapeutic Recommendations: Which TA-TMA Patients to Treat and When?

Cornelio Uderzo C^1*, Sonata Jodele², Mohamed El Missiry³, Fabio Ciceri⁴, Alessandro Busca⁵, Andrea Bacigalupo⁶ and Selim Corbacioglu⁷

¹Hematology Pediatrics DPT, Bone Marrow Transplantation Unit, S. Gerardo Hospital, Monza, University of Milan, Italy

²Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children’s Hospital medical Center, Cincinnati Ohio, USA

³Hematology Research Unit, Division of Hematology, University Central Hospital, University of Helsinki, Finland

⁴Hematology and Bone Marrow Transplantation Unit, S. Raffaele Hospital, University of Milan, Italy

⁵Azienda Ospedaliera Universitaria S.Giovanni Battista, Molinette, Torino, Italy

⁶Hematology and Bone Marrow Transplantation Unit, Ospedale S. Martino, Genova, Italy

⁷DPT of Hematology Oncology and Stem Cell Transplantation, University Children’s Hospital, Regensburg, Germany

^*Corresponding Author: Cornelio Uderzo C, Hematology Pediatrics DPT, Bone Marrow Transplantation Unit, S. Gerardo Hospital, Monza, University of Milan, Italy Email: ,